Avantor (AVTR) vs Nautilus Biotechnology (NAUT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Avantor (AVTR) has outperformed Nautilus Biotechnology (NAUT) over the past year, gaining 28.8% versus a loss of 5.4%. Over five years, NAUT leads with a -56.4% price change compared with -62.5% for AVTR. Avantor is the larger company by market cap ($10.06 billion vs $270.0 million), about 37.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AVTR | NAUT |
|---|---|---|
| Share price | $14.84 | $2.12 |
| Market cap | $10.06B | $270.03M |
| 1-day change | -1.85% | -2.30% |
| YTD return | +29.49% | +8.72% |
| 1-year return | +28.82% | -5.36% |
| 5-year return | -62.54% | -56.38% |
| P/E ratio (TTM) | 29.68 | — |
| Forward P/E | 16.73 | — |
| EPS (TTM) | $0.50 | $-0.46 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $6.55B | — |
| Revenue growth (YoY) | -3.41% | — |
| Net income (latest FY) | $-530.20M | $-59.00M |
| Gross margin | 32.65% | — |
| Operating margin | -3.76% | — |
| Net margin | -8.09% | — |
| 52-week high | $17.45 | $4.31 |
| 52-week low | $7.27 | $0.841 |
| Distance from 52-week high | -14.96% | -50.81% |
| Analyst consensus | hold | none |
| Avg. price target upside | +16.91% | +88.68% |
| Average volume | 8.77M | 6.25M |
| Shares outstanding | 677.62M | 127.37M |
| Employees | 13,500 | 128 |
| Sector | Industrials | Industrials |
| Industry | Biotechnology: Laboratory Analytical Instruments | Biotechnology: Laboratory Analytical Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Avantor is about 37.2 times larger than Nautilus Biotechnology by market value ($10.06B vs $270.03M).
- AVTR has outperformed NAUT by 34.2 percentage points over the past year.
About Avantor
AVTR stock →Avantor, Inc. engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa.
Industrials · Biotechnology: Laboratory Analytical Instruments · 13,500 employees
About Nautilus Biotechnology
NAUT stock →Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome in the United States. The company develops Nautilus Voyager Platform, which includes an end-to-end solution comprising instruments, reagents, consumables, and software analysis.
Industrials · Biotechnology: Laboratory Analytical Instruments · 128 employees
AVTR vs NAUT FAQ
Which is bigger, Avantor or Nautilus Biotechnology?
Avantor (AVTR) is larger, with a market capitalization of $10.06B compared with $270.03M for Nautilus Biotechnology (NAUT).
Which stock has performed better over the past year, AVTR or NAUT?
AVTR returned +28.82% over the past 12 months, compared with -5.36% for NAUT (price return, excluding dividends). Past performance does not predict future results.
Are Avantor and Nautilus Biotechnology in the same industry?
Yes. Both are classified in the Biotechnology: Laboratory Analytical Instruments industry within the Industrials sector.